📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

SRC/ABL inhibition disrupts CRLF2-driven signaling to induce cell death in B-cell acute lymphoblastic leukemia. (2018)

First Author: Sarno J

Attributed to: Biomedical Catalyst – Drug product production, clinical support studies, and phase 1 trial of a new MS drug funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.18632/oncotarget.25089

PubMed Identifier: 29796158

Publication URI: http://europepmc.org/abstract/MED/29796158

Type: Journal Article/Review

Volume: 9

Parent Publication: Oncotarget

Issue: 33

ISSN: 1949-2553